Paper · 33420102
Development of a structural epitope mimic: an idiotypic approach to HCV vaccine design.
Cowton VM and 11 others. NPJ Vaccines, 2021. Cited by 14 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Development of a structural epitope mimic: an idiotypic approach to HCV vaccine design. Papers, record 33420102. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33420102
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| MC_UU12014/2 | RCUK | Medical Research Council (MRC) | PubMed | ||
| 104771/Z/14/Z | Wellcome Trust (Wellcome) | PubMed | ||
| MC_EX_G0801770 | RCUK | Medical Research Council (MRC) | PubMed | ||
| Wellcome Trust | United Kingdom | PubMed | ||
| ERC-StG-2015-637304 | EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) | PubMed | ||
| MC_UU_12014/2 | Medical Research Council | United Kingdom | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References68
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 6,985,352 | Recurrent idiotopes and internal images. | EMBO J | 1982 | https://conductscience.org/library/papers/6985352 | PubMed |
| 2 | 16,369,096 | Scaling and assessment of data quality. | Acta Crystallogr D Biol Crystallogr | 2006 | https://conductscience.org/library/papers/16369096 | PubMed |
| 3 | 19,397,930 | A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication. | Antiviral Res | 2009 | https://conductscience.org/library/papers/19397930 | PubMed |
| 4 | 26,710,081 | Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge. | Hepatology | 2016 | https://conductscience.org/library/papers/26710081 | PubMed |
| 5 | 1,690,598 | Epitope mapping and use of anti-idiotypic antibodies to the L6 monoclonal anticarcinoma antibody. | Cancer Res | 1990 | https://conductscience.org/library/papers/1690598 | PubMed |
| 6 | 20,124,702 | PHENIX: a comprehensive Python-based system for macromolecular structure solution. | Acta Crystallogr D Biol Crystallogr | 2010 | https://conductscience.org/library/papers/20124702 | PubMed |
| 7 | 23,935,648 | Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies. | Clin Dev Immunol | 2013 | https://conductscience.org/library/papers/23935648 | PubMed |
| 8 | 23,698,367 | Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. | Nature | 2013 | https://conductscience.org/library/papers/23698367 | PubMed |
| 9 | 16,103,160 | Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. | J Virol | 2005 | https://conductscience.org/library/papers/16103160 | PubMed |
| 10 | 25,473,061 | Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies. | J Virol | 2015 | https://conductscience.org/library/papers/25473061 | PubMed |
1 to 10 of 68
See all 68 referencesCited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,742,346 | Anti-idiotypic antibodies as molecular mimics of conserved influenza hemagglutinin epitopes. | Protein Sci | 2026 | https://conductscience.org/library/papers/42742346 | PubMed |
| 39,852,814 | Anti-Idiotypic Antibody as a Booster Vaccine Against Respiratory Syncytial Virus. | Vaccines (Basel) | 2025 | https://conductscience.org/library/papers/39852814 | PubMed |
| 39,575,309 | Epitope-based therapeutic targets in HCV genotype 1 non-structural proteins: a novel strategy to combat emerging drug resistance. | Front Cell Infect Microbiol | 2024 | https://conductscience.org/library/papers/39575309 | PubMed |
| 38,271,227 | A novel strategy for an anti-idiotype vaccine: nanobody mimicking neutralization epitope of porcine circovirus type 2. | J Virol | 2024 | https://conductscience.org/library/papers/38271227 | PubMed |
| 37,647,422 | Therapeutic strategies and promising vaccine for hepatitis C virus infection. | Immun Inflamm Dis | 2023 | https://conductscience.org/library/papers/37647422 | PubMed |
| 36,934,116 | Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity. | NPJ Vaccines | 2023 | https://conductscience.org/library/papers/36934116 | PubMed |
| 36,482,074 | Potential of an anti-bevacizumab idiotype scFv DNA-based immunization to elicit VEGF-binding antibody response. | Gene Ther | 2023 | https://conductscience.org/library/papers/36482074 | PubMed |
| 36,379,958 | Two-component vaccine consisting of virus-like particles displaying hepatitis C virus envelope protein 2 oligomers. | NPJ Vaccines | 2022 | https://conductscience.org/library/papers/36379958 | PubMed |
| 35,761,816 | Production and immunogenicity of different prophylactic vaccines for hepatitis C virus (Review). | Exp Ther Med | 2022 | https://conductscience.org/library/papers/35761816 | PubMed |
| 35,015,104 | [Development approaches for vaccines against hepatitis C virus infections]. | Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz | 2022 | https://conductscience.org/library/papers/35015104 | PubMed |
1 to 10 of 12
See all 12 cited byGenes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| FANCB | 2,187 | PubTator's text mining | https://conductscience.org/library/genes/2187 | NCBI Gene |
| IGK | 50,802 | PubTator's text mining | https://conductscience.org/library/genes/50802 | NCBI Gene |
| LIPC | 3,990 | PubTator's text mining | https://conductscience.org/library/genes/3990 | NCBI Gene |
| MBP | 4,155 | PubTator's text mining | https://conductscience.org/library/genes/4155 | NCBI Gene |
| SCFV | 652,070 | PubTator's text mining | https://conductscience.org/library/genes/652070 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33420102
GET https://conductscience.org/api/papers/v1/33420102/references?page=2